Experimental drug pomalidomide tested in rare blood cancer

NCT ID NCT01198067

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested the drug pomalidomide in 15 people with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or was not responding to prior treatments. The goal was to find the safest dose and see how the drug affects the immune system and cancer growth. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pomalidomide
What this could lead to: If successful, this could point toward a new treatment option for patients with Waldenstrom macroglobulinemia that has returned or stopped responding to other therapies.
What could go wrong: This is a very early phase I trial with only 15 participants, so results are preliminary. The study was terminated, and it is unknown if pomalidomide will prove safe or effective in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT WALDENSTROM MACROGLOBULINEMIA REFRACTORY WALDENSTROM MACROGLOBULINEMIA

Experimental drug pomalidomide tested in rare blood cancer

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions